Parker-Lue S, Santoro M, Koski G. The Ethics and economics of pharmaceutical pricing. Annu Rev Pharmacol Toxicol. 2015;55:191–206.
Article
CAS
PubMed
Google Scholar
Vogler S, Paris V, Ferrario A, Wirtz VJ, de Joncheere K, Schneider P, et al. How can pricing and reimbursement policies improve affordable access to medicines? Lessons learned from European countries. Appl Health Econ Health Policy. 2017;15(3):307–21.
Article
PubMed
Google Scholar
Light DW, Kantarjian H. Market spiral pricing of cancer drugs. Cancer. 2013;119(22):3900–2.
Article
PubMed
Google Scholar
Teferra S, Hanlon C, Beyero T, Jacobsson L, Shibre T. Perspectives on reasons for non-adherence to medication in persons with schizophrenia in Ethiopia: a qualitative study of patients, caregivers and health workers. BMC Psychiatry. 2013;13(1):1–9.
Article
Google Scholar
Bigdeli M, Laing R, Tomson G, Babar ZU. Medicines and universal health coverage: challenges and opportunities. J Pharm Policy Pract. 2015;8(1):1–3.
Article
Google Scholar
Ghebreyesus TA. All roads lead to universal health coverage. Lancet Glob Health. 2017;5(9):e839–e40.
Article
PubMed
Google Scholar
Wirtz VJ, Hogerzeil HV, Gray AL, Bigdeli M, De Joncheere CP, Ewen MA, et al. Essential medicines for universal health coverage. 2017.
Book
Google Scholar
World Health Organization. WHO guideline on country pharmaceutical pricing policies. 2nd ed. Geneva: World Health Organization; 2020. p. 1.
Google Scholar
Acosta A, Acosta A, Ciapponi A, Aaserud M, Vietto V, Austvoll-Dahlgren A, et al. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database Syst Rev. 2014;2014(10):1-107.
Robinson JC, Whaley CM, Brown TT. Association of reference pricing with drug selection and spending. N Engl J Med. 2017;377(7):658–65.
Article
PubMed
PubMed Central
Google Scholar
World Health Organization. Assessment of medicine pricing and reimbursement systems in health insurance schemes. 2016.
Google Scholar
Wouters OJ, Kanavos PG, McKee M. Comparing generic drug markets in Europe and the United States: prices, volumes, and spending; 2017.
Google Scholar
Galizzi MM, Ghislandi S, Miraldo M. Effects of reference pricing in pharmaceutical markets: a review. Pharmacoeconomics. 2011;29(1):17–33.
Article
PubMed
Google Scholar
Adriaen M, De Witte K, Simoens S. Pricing strategies of originator and generic medicines following patent expiry in Belgium. J Generic Med. 2008;5(3):175–87.
Article
Google Scholar
Bashaar M, Hassali MA, Saleem F, ALrasheedy AA, Thawani V, Babar ZUD. Efficacy of international approaches to medicine price regulation and control: a scoping review. J Appl Pharm Sci. 2017;7(4):227–41.
Google Scholar
Beall RF, Nickerson JW, Attaran A. Pan-Canadian overpricing of medicines: a 6-country study of cost control for generic medicines. Open Med. 2014;8(4):130–5.
Google Scholar
Cho MH, Yoo KB, Lee HY, Lee KS, Kwon JA, Han KT, et al. The effect of new drug pricing systems and new reimbursement guidelines on pharmaceutical expenditures and prescribing behavior among hypertensive patients in Korea. Health Policy (Amsterdam, Netherlands). 2015;119(5):604–11.
Article
PubMed
Google Scholar
Woutersa OJ, Kanavosa PG. Transitioning to a national health system in Cyprus: a stakeholder analysis of pharmaceutical policy reform. Bull World Health Organ. 2015;93:606–13.
Article
Google Scholar
Frye JE. International drug price indicator guide. Arlington: Management Sciences for Health[Google Scholar]; 2012.
Google Scholar
Hinsch M, Kaddar M, Schmitt S. Enhancing medicine price transparency through price information mechanisms. Glob Health. 2014;10(1):1–11.
Article
Google Scholar
World Health Organization, Health Action International. Measuring medicine prices, availability, affordability and price components. Geneva; Amersterdam: World Health Organization; Health Action International; 2008.
Google Scholar
Nguyen TA, Knight R, Roughead EE, Brooks G, Mant A. Policy options for pharmaceutical pricing and purchasing: issues for low-and middle-income countries. Health Policy Plan. 2015;30(2):267–80.
Article
PubMed
Google Scholar
Ahmad NS, Makmor-Bakry M, Hatah E. Drug price transparency initiative: a scoping review. Res Soc Adm Pharm. 2020;20:20.
Google Scholar
Eaton J. Ensuring access to psychotropic medication in sub-Saharan Africa. Afr J Psychiatry (South Africa). 2008;11(3):179–81.
CAS
Google Scholar
Mousnad MA, Shafie AA, Ibrahim MI. Systematic review of factors affecting pharmaceutical expenditures. Health Policy. 2014;116(2-3):137–46.
Article
PubMed
Google Scholar
Pereira S, Jawahar N. The development and future of BRICS countries in the pharmaceutical sector. J Pharm Sci Res. 2018;10(6):1336–41.
Google Scholar
Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160.
Article
PubMed
PubMed Central
Google Scholar
Mirzoev T, Koduah A, de Chavez AC, Baatiema L, Danso-Appiah A, Ensor T, et al. Implementation of medicines pricing policies in sub-Saharan Africa: protocol for a systematic review. BMJ Open. 2021;11(2):e044293.
Article
PubMed
PubMed Central
Google Scholar
World Health Organization. Institutional Repository for Information Sharing (IRIS). 2021. https://apps.who.int/iris/.
Google Scholar
World Bank. Open Knowledge Repository (OKR). 2021. https://openknowledge.worldbank.org/.
Google Scholar
University of Montreal. Erudit (Observatoire des sciences et des technologies). 2021. https://www.erudit.org/en/.
Google Scholar
Cairn International. Cairn Info International. 2021. https://www.cairn.info/.
Google Scholar
McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75:40–6.
Article
PubMed
Google Scholar
Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):1–10.
Article
Google Scholar
Joanna Briggs Institute. Checklist for analytical cross sectional studies. 2017. https://jbi.global/sites/default/files/2019-05/JBI_Critical_Appraisal-Checklist_for_Analytical_Cross_Sectional_Studies2017_0.pdhttps://jbi.global/sites/default/files/2019-05/JBI_Critical_Appraisal-Checklist_for_Analytical_Cross_Sectional_Studies2017_0.pdf.
Google Scholar
Joanna Briggs Institute. Checklist for qualitative research. 2017. https://jbi.global/sites/default/files/2019-05/JBI_Critical_Appraisal-Checklist_for_Qualitative_Research2017_0.pdf.
Google Scholar
Joanna Briggs Institute. Checklist for cohort studies. 2017. https://jbi.global/sites/default/files/2019-05/JBI_Critical_Appraisal-Checklist_for_Cohort_Studies2017_0.pdf.
Google Scholar
Snilstveit B, Oliver S, Vojtkova M. Narrative approaches to systematic review and synthesis of evidence for international development policy and practice. J Dev Effect. 2012;4(3):409–29.
Article
Google Scholar
Ali G, Yahia A. Controlling medicine prices in Sudan: the challenge of the recently established medicines regulatory authority. East Mediterr Health J. 2012;18(8):811–20.
Article
CAS
PubMed
Google Scholar
Smith N, Obala A, Simiyu C, Menya D, Khwa-Otsyula B, O'Meara WP. Accessibility, availability and affordability of anti-malarials in a rural district in Kenya after implementation of a national subsidy scheme. Malar J. 2011;10(1):1–9.
Article
Google Scholar
Sabot OJ, Mwita A, Cohen JM, Ipuge Y, Gordon M, Bishop D, et al. Piloting the global subsidy: the impact of subsidized artemisinin-based combination therapies distributed through private drug shops in rural Tanzania. PLoS One. 2009;4(9):e6857.
Article
PubMed
PubMed Central
Google Scholar
Ponsar F, Van Herp M, Zachariah R, Gerard S, Philips M, Jouquet G. Abolishing user fees for children and pregnant women trebled uptake of malaria-related interventions in Kangaba, Mali. Health Policy Plan. 2011;26(suppl_2):ii72–83.
PubMed
Google Scholar
Maïga D, Williams-Jones B. Assessment of the impact of market regulation in Mali on the price of essential medicines provided through the private sector. Health Policy. 2010;97(2-3):130–5.
Article
PubMed
Google Scholar
Fink G, Dickens WT, Jordan M, Cohen JL. Access to subsidized ACT and malaria treatment—evidence from the first year of the AMFm program in six districts in Uganda. Health Policy Plan. 2014;29(4):517–27.
Article
PubMed
Google Scholar
Tran DN, Manji I, Njuguna B, Kamano J, Laktabai J, Tonui E, et al. Solving the problem of access to cardiovascular medicines: revolving fund pharmacy models in rural western Kenya. BMJ Glob Health. 2020;5(11):e003116.
Article
PubMed
PubMed Central
Google Scholar
Steyn R, Burger JR, Serfontein JHP, Lubbe MS. Influence of a new reference-based pricing system in South Africa on the prevalence and cost of antidiabetic medicine: a pilot study. Int J Pharm Pract. 2007;15(4):307–11.
Article
Google Scholar
de Jager H, Suleman F. The impact of generics and generic reference pricing on candesartan and rosuvastatin utilisation, price and expenditure in South Africa. Int J Clin Pharm. 2019;41(1):81–7.
Article
PubMed
Google Scholar
Cohen JL, Yadav P, Moucheraud C, Alphs S, Larson PS, Arkedis J, et al. Do price subsidies on artemisinin combination therapy for malaria increase household use? Evidence from a repeated cross-sectional study in remote regions of Tanzania. PLoS One. 2013;8(7):e70713.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ali GKM. Accessibility of medicines and primary health care: the impact of the revolving drug fund in Khartoum state. Afr J Pharm Pharmacol. 2009;3(3):70–7.
Google Scholar
Moodley R, Suleman F. The impact of the single exit price policy on a basket of generic medicines in South Africa, using a time series analysis from 1999 to 2014. PLoS One. 2019;14(7):e0219690.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ye Y, Arnold F, Noor A, Wamukoya M, Amuasi J, Blay S, et al. The Affordable Medicines Facility-malaria (AMFm): are remote areas benefiting from the intervention? Malar J. 2015;14(1):398.
Article
PubMed
PubMed Central
Google Scholar
Maiga D, Maiga S, Maiga M. Mechanism and implication of regulation of the pricing of essential medicines in the private pharmaceutical sector in Mali. Med Trop. 2010;70(2):184–8.
CAS
Google Scholar
Ongarora D, Karumbi J, Minnaard W, Abuga K, Okungu V, Kibwage I. Medicine prices, availability, and affordability in private health facilities in low-income settlements in Nairobi County, Kenya. Pharmacy (Basel). 2019;7(2):40.
Article
PubMed
Google Scholar
Bangalee V, Suleman F. Has the increase in the availability of generic drugs lowered the price of cardiovascular drugs in South Africa? Health SA Gesondheid. 2016;21:60–6.
Article
Google Scholar
Tougher S, Mann AG, Ye Y, Kourgueni IA, Thomson R, Amuasi JH, et al. Improving access to malaria medicine through private-sector subsidies in seven African countries. Health Aff (Millwood). 2014;33(9):1576–85.
Article
PubMed
Google Scholar
Honda A, Hanson K. Do equity funds protect the poor? Case studies from north-western Madagascar. Health Policy Plan. 2013;28(1):75–89.
Article
PubMed
Google Scholar
Bangalee V, Suleman F. Pseudo-generics in South Africa: a price comparison. Value Health Reg Issues. 2019;19:87–91.
Article
PubMed
PubMed Central
Google Scholar
d'Almeida C, Essi M-J, Camara M, Coriat B. Access to second-line antiretroviral therapeutic regimens in low-resource settings: experiences from Cameroon. J Acquir Immune Defic Syndr. 2011;57:S55–S8.
Article
PubMed
Google Scholar
Liu Y, Galárraga O. Do national drug policies influence antiretroviral drug prices? Evidence from the southern African development community. Health Policy Plan. 2017;32(2):170–7.
PubMed
Google Scholar
Wiedenmayer K, Mbwasi R, Mfuko W, Mpuya E, Charles J, Chilunda F, et al. Jazia prime vendor system-a public-private partnership to improve medicine availability in Tanzania: from pilot to scale. J Pharm Policy Pract. 2019;12(1):1–10.
Article
Google Scholar
Moodley R, Suleman F. Evaluating the impact of the single exit price policy on a basket of originator medicines in South Africa from 1999 to 2014 using a time series analysis. BMC Health Serv Res. 2019;19(1):1–13.
Article
Google Scholar
Suleman F, Cassar K. The impact of international benchmarking on the price of immunosuppressive medicines for transplant recipients in South Africa. S Afr Med J. 2019;109(11):865–71.
Article
Google Scholar
Nicolosi E, Gray A. Potential cost savings from generic medicines—protecting the prescribed minimum benefits. S Afr Fam Pract. 2009;51(1):59–63.
Article
Google Scholar
Walwyn DR, Nkolele AT. An evaluation of South Africa’s public–private partnership for the localisation of vaccine research, manufacture and distribution. Health Res Policy Syst. 2018;16(1):1–17.
Article
Google Scholar
Guimier JM, Candau D, Garenne M, Teulières L. Why drug prices are high in sub-Saharan Africa. analysis of price structure: the case of Senegal. Cahiers d'études et de recherches francophones/Santé. 2005;15(1):41–52.
Google Scholar
Rothberg A, Blignault J, Serfontein C, Valodia B, Eekhout S, Pels L. Experience of a medicines reference-pricing model. S Afr Med J. 2004;94(3):183–8.
CAS
PubMed
Google Scholar
Ashigbie PG, Azameti D, Wirtz VJ. Challenges of medicines management in the public and private sector under Ghana’s National Health Insurance Scheme–a qualitative study. J Pharm Policy Pract. 2016;9(1):1–10.
Article
Google Scholar
Wilson KR, Kohler JC, Ovtcharenko N. The make or buy debate: considering the limitations of domestic production in Tanzania. Glob Health. 2012;8(1):1–9.
Article
Google Scholar
Maïga FI, Haddad S, Fournier P, Gauvin L. Public and private sector responses to essential drugs policies: a multilevel analysis of drug prescription and selling practices in Mali. Soc Sci Med. 2003;57(5):937–48.
Article
PubMed
Google Scholar
Abdel Rida N, Mohamed Ibrahim MI, Babar Z-U-D, Owusu Y. A systematic review of pharmaceutical pricing policies in developing countries. J Pharm Health Serv Res. 2017;8(4):213–26.
Article
Google Scholar
Danzon PM, Chao L-W. Does regulation drive out competition in pharmaceutical markets? J Law Econ. 2000;43(2):311–58.
Article
Google Scholar
Henry D, Searles A. Chapter 9: pharmaceutical pricing policy. In: Management sciences for health, MDS-3: managing access to medicines and health technologies; 2012.
Google Scholar
Sood N, De Vries H, Gutierrez I, Lakdawalla DN, Goldman DP. The effect of regulation on pharmaceutical revenues: experience in nineteen countries: if the United States implemented price controls and negotiations similar to those in other developed countries, US revenues would fall by as much as 20.3 percent. Health Aff. 2008;27(Suppl1):w125–w37.
Article
Google Scholar
Selvaraj S, Hasan H, Chokshi M, Sengupta A, Guha A, Shiva M, et al. Pharmaceutical pricing policy: a critique. Econ Polit Wkly. 2012;47:20–3.
Dylst P, Simoens S. Generic medicine pricing policies in Europe: current status and impact. Pharmaceuticals (Basel). 2010;3(3):471–81.
Article
PubMed
Google Scholar
Suzuki M, Webb D, Small R. Competing frames in global health governance: an analysis of stakeholder influence on the political declaration on non-communicable diseases. Int J Health Policy Manag. 2021. https://doi.org/10.34172/ijhpm.2020.257.
Balane MA, Palafox B, Palileo-Villanueva LM, McKee M, Balabanova D. Enhancing the use of stakeholder analysis for policy implementation research: towards a novel framing and operationalised measures. BMJ Glob Health. 2020;5(11):e002661.
Article
PubMed
PubMed Central
Google Scholar
Ancker S, Rechel B. HIV/AIDS policy-making in Kyrgyzstan: a stakeholder analysis. Health Policy Plan. 2015;30(1):8–18.
Article
PubMed
Google Scholar
Brugha R, Varvasovszky Z. Stakeholder analysis: a review. Health Policy Plan. 2000;15(3):239–46.
Article
CAS
PubMed
Google Scholar
Parashar R, Gawde N, Gilson L. Application of “actor interface analysis” to examine practices of power in health policy implementation: an interpretive synthesis and guiding steps. Int J Health Policy Manag. 2020;10.
Lehmann U, Gilson L. Actor interfaces and practices of power in a community health worker programme: a South African study of unintended policy outcomes. Health Policy Plan. 2013;28(4):358–66.
Article
PubMed
Google Scholar
Cleary S, Molyneux S, Gilson L. Resources, attitudes and culture: an understanding of the factors that influence the functioning of accountability mechanisms in primary health care settings. BMC Health Serv Res. 2013;13(1):320.
Article
PubMed
PubMed Central
Google Scholar
Sriram V, Topp SM, Schaaf M, Mishra A, Flores W, Rajasulochana SR, et al. 10 best resources on power in health policy and systems in low- and middle-income countries. Health Policy Plan. 2018;33(4):611–21.
Article
PubMed
Google Scholar
Regmi K, Mudyarabikwa O. A systematic review of the factors - barriers and enablers - affecting the implementation of clinical commissioning policy to reduce health inequalities in the National Health Service (NHS), UK. Public Health. 2020;186:271–82.
Article
CAS
PubMed
Google Scholar
Vejaratnam N, Mohamad ZF, Chenayah S. A systematic review of barriers impeding the implementation of government green procurement. J Public Procure. 2020;20(4):451–71.
Article
Google Scholar
Anggriani Y, Ibrahim MIM, Suryawati S, Shafie AA. The impact of Indonesian generic medicine pricing policy on medicine prices. J Generic Med. 2013;10(3-4):219–29.
Article
Google Scholar
Kaló Z, Alabbadi I, Al Ahdab OG, Alowayesh M, Elmahdawy M, Al-Saggabi AH, et al. Implications of external price referencing of pharmaceuticals in Middle East countries. Expert Rev Pharmacoecon Outcomes Res. 2015;15(6):993–8.
Article
PubMed
Google Scholar
Ye Y, Arnold F, Noor A, Wamukoya M, Amuasi J, Blay S, et al. The Affordable Medicines Facility-malaria (AMFm): are remote areas benefiting from the intervention? Malar J. 2015;14(1):1–11.
Article
Google Scholar
Tougher S, Mann AG, Group A, Ye Y, Kourgueni IA, Thomson R, et al. Improving access to malaria medicine through private-sector subsidies in seven African countries. Health Aff. 2014;33(9):1576–85.
Article
Google Scholar
Mirzoev T, Das M, Ebenso B, Uzochukwu B, Rawat B, Blok L, et al. Contextual influences on the role of evidence in health policy development: what can we learn from six policies in India and Nigeria? Evid Policy. 2017;13(1):59–79.
Article
Google Scholar
Koduah A, van Dijk H, Agyepong IA. The role of policy actors and contextual factors in policy agenda setting and formulation: maternal fee exemption policies in Ghana over four and a half decades. Health Res Policy Syst. 2015;13(1):27.
Article
PubMed
PubMed Central
Google Scholar
Verboom B, Baumann A. Mapping the qualitative evidence base on the use of research evidence in health policy-making: a systematic review. Int J Health Policy Manag. 2020. https://doi.org/10.34172/ijhpm.2020.201.
Mirzoev T, Poudel AN, Gissing S, Doan TTD, Ferdous T, Regmi S, et al. Is evidence-informed urban health planning a myth or reality? Lessons from a qualitative assessment in three Asian cities. Health Policy Plan. 2019;34(10):773–83.
Article
PubMed
PubMed Central
Google Scholar
Shroff Z, Aulakh B, Gilson L, Agyepong I, El-Jardali F, Ghaffar A. Incorporating research evidence into decision-making processes: researcher and decision-maker perceptions from five low- and middle-income countries. Health Res Policy Syst. 2015;13(1):70.
Article
PubMed
PubMed Central
Google Scholar
Moat KA, Lavis JN. 10 best resources for … evidence-informed health policy making. Health Policy Plan. 2013;28(2):215–8.
Article
PubMed
Google Scholar
Mirzoev T, Green A, Gerein N, Pearson S, Bird P, Ha BTT, et al. Role of evidence in maternal health policy processes in Vietnam, India and China: findings from the HEPVIC project. Evid Policy. 2013;9(4):493–511.
Article
Google Scholar
Mbava N, Dahler-Larsen P. Evaluation in African contexts: the promises of participatory approaches in theory-based evaluations. Afr Eval J. 2019;7(1):1–9.
Article
Google Scholar
Ebenso B, Manzano A, Uzochukwu B, Etiaba E, Huss R, Ensor T, et al. Dealing with context in logic model development: reflections from a realist evaluation of a community health worker programme in Nigeria. Eval Prog Plann. 2019;73:97–110.
Article
Google Scholar
Ogbuabor DC, Onwujekwe OE. Implementation of free maternal and child healthcare policies: assessment of influence of context and institutional capacity of health facilities in south-east Nigeria. Glob Health Action. 2018;11(1):1535031.
Article
PubMed
PubMed Central
Google Scholar
Greenhalgh T, Pawson R, Wong G, Westhorp G, Greenhalgh J, Manzano A, et al. What realists mean by context; or, why nothing works everywhere or for everyone: the Rameses II project; 2017.
Google Scholar